Thus, Sipa1 deficiency uncovers a host immune mechanism potentially capable of eradicating Bcr-Abl<sup>+</sup> HPCs via coordinated interplay between MSCs and immune T cells, which may provide a clue for radical control of human CML.
SPA-1-deficient mice developed a spectrum of myeloid disorders that resembled human chronic myelogenous leukemia (CML) in chronic phase, CML in blast crisis, and myelodysplastic syndrome as well as anemia.
SPA-1-deficient mice developed a spectrum of myeloid disorders that resembled human chronic myelogenous leukemia (CML) in chronic phase, CML in blast crisis, and myelodysplastic syndrome as well as anemia.